Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Weight and Metabolic Changes After Switching From Tenofovir Alafenamide/Emtricitabine (FTC)+Dolutegravir (DTG), Tenofovir Disoproxil Fumarate (TDF)/FTC + DTG, and TDF/FTC/Efavirenz to TDF/Lamivudine/DTG

Clinical Infectious Diseases(2022)10.1093/cid/ciac949Source: DataRank Database

Weight and Metabolic Changes After Switching From Tenofovir Alafenamide/Emtricitabine (FTC)+Dolutegravir (DTG), Tenofovir Disoproxil Fumarate (TDF)/FTC + DTG, and TDF/FTC/Efavirenz to TDF/Lamivudine/DTG is a research paper published in Clinical Infectious Diseases (2022). On theSindex it has a DataRank of 0. It has been cited 57 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access57 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 13.40)OA: bronzeTopics (49)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (9)

Godspower Akpomiemie ORCID,Nomathemba Chandiwana ORCID,Simiso Sokhela ORCID,Andrew Hill ORCID,Kaitlyn McCann ORCID

Live enrichment

PubMed:36519389 OpenAlex:https://openalex.org/W4311578047

National Heart, Lung and Blood Institute

Grant: UG3HL156388

National Institutes of Health

Grant: 2016-07-Wits RHI.

National Institutes of Health

Grant: 1UG3HL156388-01

Integrating HIV and hEART health in South Africa (iHeart-SA)

FWCI

13.40

Citation Percentile

1.0%

Influential Citations

Citation Trend

2023

2024

2025

2026

bronzeLicense: OUP Standard Publication Reuse

journalhttps://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciac949/48518879/ciac949.pdf

BRONZEhttps://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciac949/48518879/ciac949.pdf

publisherhttps://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciac949/48518879/ciac949.pdf

publisherhttps://academic.oup.com/cid/article-pdf/76/8/1492/50001415/ciac949.pdf

journalhttps://doi.org/10.1093/cid/ciac949

Fields of Study

HIV-related health complications and treatmentsHIV/AIDS drug development and treatmentHIV/AIDS Research and InterventionsMedicine0303 health sciences03 medical and health sciencesHumansLamivudineTenofovirEmtricitabineHIV InfectionsBenzoxazinesAdenineAnti-HIV AgentsDolutegravirAlkynesCyclopropanes

MeSH Terms

EmtricitabineTenofovirDolutegravirAdenineAlkynesCyclopropanesHumansHIV InfectionsLamivudineAnti-HIV AgentsBenzoxazines

Keywords

Tenofovir alafenamideEmtricitabineDolutegravirEfavirenzMedicineLamivudinePharmacologyVirologyHuman immunodeficiency virus (HIV)Viral loadHepatitis B virusCyclopropanesAnti-HIV AgentsAdenineHIV InfectionsBenzoxazinesAlkynesHumansTenofovirHIVbody weight

Sustainable Development Goals

SDG 3: 3. Good health